Dganit Dinour1, Liat Ganon, Levin-Iaina Nomy, Rotem Ron, Eliezer J Holtzman. 1. Department of Nephrology and Hypertension, The Chaim Sheba Medical Center, Tel-Hashomer and the Faculty of Medicine, Sackler School of Medicine, Sheba Medical Center, 52621, Tel-Aviv, Israel, Dganit.Dinour@sheba.health.gov.il.
Abstract
BACKGROUND: Uromodulin (Tamm-Horsfall protein) is the most abundant urinary protein in healthy individuals. Despite 60 years of research, its physiological role remains rather elusive. Familial juvenile hyperuricemic nephropathy and medullary cystic kidney disease Type 2 are autosomal dominant tubulointerstitial nephropathies characterized by gouty arthritis and progressive renal insufficiency, caused by uromodulin (UMOD) mutations. The aim of this study was to compare the cellular effects of mutant and wild-type UMOD. METHODS: Wild-type UMOD cDNA was cloned from human kidney cDNA into pcDNA3 expression vector. A mutant UMOD construct, containing the previously reported mutation, V273, was created by in vitro mutagenesis. Transient and stable transfection studies were performed in human embryonic kidney cells and mouse distal convoluted tubular cells, respectively. Expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR), western blot and immunofluorescence. Oligosaccharide cleavage by glycosidases was performed to characterize different forms of UMOD. Nuclear translocation of P65 and degradation of IκBα and IRAK1 in response to interleukin (IL)-1β were used to evaluate the effects of wild-type and mutant UMOD on the IL-1R-NFκB pathway. RESULTS: The mutant protein was shown to be retained in the endoplasmic reticulum and was not excreted to the cell medium, as opposed to the wild-type protein. NFκB activation in cells expressing mutant UMOD was similar to that of untransfected cells. In contrast, cells over-expressing wild-type UMOD showed markedly reduced NFκB activation. CONCLUSION: Our findings suggest that UMOD may have a physiologic function related to its inhibitory effect on the NFκB pathway.
BACKGROUND:Uromodulin (Tamm-Horsfall protein) is the most abundant urinary protein in healthy individuals. Despite 60 years of research, its physiological role remains rather elusive. Familial juvenile hyperuricemic nephropathy and medullary cystic kidney disease Type 2 are autosomal dominant tubulointerstitial nephropathies characterized by gouty arthritis and progressive renal insufficiency, caused by uromodulin (UMOD) mutations. The aim of this study was to compare the cellular effects of mutant and wild-type UMOD. METHODS: Wild-type UMOD cDNA was cloned from human kidney cDNA into pcDNA3 expression vector. A mutant UMOD construct, containing the previously reported mutation, V273, was created by in vitro mutagenesis. Transient and stable transfection studies were performed in humanembryonic kidney cells and mouse distal convoluted tubular cells, respectively. Expression was evaluated by reverse transcription polymerase chain reaction (RT-PCR), western blot and immunofluorescence. Oligosaccharide cleavage by glycosidases was performed to characterize different forms of UMOD. Nuclear translocation of P65 and degradation of IκBα and IRAK1 in response to interleukin (IL)-1β were used to evaluate the effects of wild-type and mutant UMOD on the IL-1R-NFκB pathway. RESULTS: The mutant protein was shown to be retained in the endoplasmic reticulum and was not excreted to the cell medium, as opposed to the wild-type protein. NFκB activation in cells expressing mutant UMOD was similar to that of untransfected cells. In contrast, cells over-expressing wild-type UMOD showed markedly reduced NFκB activation. CONCLUSION: Our findings suggest that UMOD may have a physiologic function related to its inhibitory effect on the NFκB pathway.
Authors: Marcus D Säemann; Thomas Weichhart; Maximilian Zeyda; Günther Staffler; Michael Schunn; Karl M Stuhlmeier; Yuri Sobanov; Thomas M Stulnig; Shizuo Akira; Alexander von Gabain; Uwe von Ahsen; Walter H Hörl; Gerhard J Zlabinger Journal: J Clin Invest Date: 2005-02 Impact factor: 14.808
Authors: P Vylet'al; M Kublová; M Kalbácová; K Hodanová; V Baresová; B Stibůrková; J Sikora; H Hůlková; J Zivný; J Majewski; A Simmonds; J-P Fryns; G Venkat-Raman; M Elleder; S Kmoch Journal: Kidney Int Date: 2006-08-02 Impact factor: 10.612
Authors: Anna Köttgen; Shih-Jen Hwang; Martin G Larson; Jennifer E Van Eyk; Qin Fu; Emelia J Benjamin; Abbas Dehghan; Nicole L Glazer; W H Linda Kao; Tamara B Harris; Vilmundur Gudnason; Michael G Shlipak; Qiong Yang; Josef Coresh; Daniel Levy; Caroline S Fox Journal: J Am Soc Nephrol Date: 2009-12-03 Impact factor: 10.121
Authors: Siân E Williams; Anita A C Reed; Juris Galvanovskis; Corinne Antignac; Tim Goodship; Fiona E Karet; Peter Kotanko; Karl Lhotta; Vincent Morinière; Paul Williams; William Wong; Patrik Rorsman; Rajesh V Thakker Journal: Hum Mol Genet Date: 2009-05-22 Impact factor: 6.150